CARsgen Extends Share Buyback Plan as Major Shareholder Raises Stake
I'm PortAI, I can summarize articles.
CARsgen Therapeutics Holdings Ltd. has extended its share buyback plan until the next annual general meeting, having repurchased 7,627,000 shares. The buyback is funded by non-IPO sources and aims to enhance shareholder value, indicating the company's belief that its shares are undervalued. Additionally, YIJIE Biotech Holding Limited has increased its stake to 38.2%, reflecting market confidence in CARsgen's long-term prospects. The latest analyst rating for CARsgen's stock is a 'Sell' with a HK$14.92 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments